Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.

Autor: Castellazzi M; Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44124 Ferrara, Italy., Delbue S; Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy., Elia F; Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy., Gastaldi M; Department of General Neurology, National Neurological Institute C. Mondino, 27100 Pavia, Italy., Franciotta D; Department of General Neurology, National Neurological Institute C. Mondino, 27100 Pavia, Italy., Rizzo R; Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy., Bellini T; Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44124 Ferrara, Italy., Bergamaschi R; Department of General Neurology, National Neurological Institute C. Mondino, 27100 Pavia, Italy., Granieri E; Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44124 Ferrara, Italy., Fainardi E; Department of Neurosciences and Rehabilitation, Azienda Ospedaliero-Universitaria, 44124 Ferrara, Italy.
Jazyk: angličtina
Zdroj: Disease markers [Dis Markers] 2015; Vol. 2015, pp. 901312. Date of Electronic Publication: 2015 May 26.
DOI: 10.1155/2015/901312
Abstrakt: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system. Natalizumab, a humanized anti-α4 integrin monoclonal antibody, is a highly effective treatment approved for MS. An association between MS and an exposure to Epstein-Barr Virus (EBV) sustained by the levels of antiviral capsid antigen (VCA) and anti-Epstein-Barr nuclear antigen-1 (EBNA-1) IgG has been described. Our goal was to verify the utility of EBV-specific IgG as a marker in Natalizumab treated MS. Twenty patients (17 female and 3 male) in treatment with Natalizumab were enrolled. Serum levels of anti-VCA and anti-EBNA-1 IgG were determined and expressed as arbitrary units (AU) before treatment and every three months for 21 months of therapy. Anti-VCA IgG levels were increased at the 15th month (235410 ± 196712 AU) comparing with the 3rd (98146 ± 47145 AU) and the 6th (109866 ± 52270 AU) months of therapy (p < 0.05). No significant differences were found for serum anti-EBNA-1 IgG levels. Our data indicate that a transient, self-limited, EBV reactivation can occur in MS during Natalizumab therapy but our results do not support the use of serum EBV-specific antibody levels as biomarkers for monitoring therapeutic response to Natalizumab in the course of MS.
Databáze: MEDLINE
Externí odkaz: